Drug Pricing Hearing In Senate Postponed, Handing Innovators Another Victory
Executive Summary
First hearing in Sen. Alexander's committee was dominated by Democrat complaints about Obamacare repeal; now that there's an actual bill to criticize, the next one might have been even worse, but regardless of the reason, the postponement means innovator prices get to stay out of the spotlight once again.
You may also be interested in...
Drug Pricing, Supply Chain Issues May Get House Hearing
Energy & Commerce Health Subcommittee is considering a hearing, but leadership may be concerned Democrats will use the session to air grievances over Republican efforts to repeal the Affordable Care Act.
FDARA Takes Effect With Under-The-Radar Presidential Signature
Key FDA legislation moves to implementation phase with presidential signature but little fanfare.
FDARA Takes Effect With Under-The-Radar Presidential Signature
Key FDA legislation moves to implementation phase with presidential signature but little fanfare.